Vitamin K antagonist use in patients ≥90 years was associated with a mildly increased risk of bleeding (HR 1.26; 95% CI 1.05-1.50) and a higher risk of thrombosis compared to patients in their 70s.
Cohort (n=3,313)
Does advancing age (≥80 years) increase the risk of bleeding and thrombosis in patients treated with vitamin K antagonists compared to patients aged 70-79 years?
In patients treated with vitamin K antagonists, advancing age beyond 80 years is associated with a sharp increase in thrombotic risk but only a mild increase in bleeding risk.
Effect estimate: HR 1.26 (95% CI 1.05-1.50)
Absolute Event Rate: 18.1% vs 14.8%
IMPORTANCE: Previous studies have shown that, despite the higher risk of bleeding, the elderly still benefit from taking anticoagulants if they have a stringent indication. However, owing to the relatively low number of patients older than 90 years in these studies, it is unknown whether this benefit is also seen with the eldest patients. OBJECTIVE: To determine how the risk of bleeding and thrombosis is associated with age in patients older than 70 years who were treated with a vitamin K antagonist (VKA). DESIGN, SETTING, AND PARTICIPANTS: A matched cohort study was conducted of patients at a thrombosis service who were treated with a VKA between January 21, 2009, and June 30, 2012. All 1109 patients 90 years or older who were treated with a VKA were randomly matched 1:1:1 with 1100 patients aged 80 to 89 years and 1104 patients aged 70 to 79 years based on duration of VKA treatment. Data analysis was conducted from April 2015 to April 2016. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of clinically relevant nonmajor and major bleeding. Secondary outcomes included thromboses and quality of VKA control. RESULTS: During 6419 observation-years, 713 of the 3313 patients (1394 men and 1919 women) had 1050 bleeding events. The risk of bleeding was not significantly increased in patients aged 80 to 89 years (event rate per 100 patient-years ER, 16.7; hazard ratio HR, 1.07; 95% CI, 0.89-1.27) and mildly increased in patients 90 years or older (ER, 18.1; HR, 1.26; 95% CI, 1.05-1.50) compared with patients aged 70 to 79 years (ER, 14.8). The point estimates for major bleeding (including fatal) were comparable for patients aged 80 to 89 years (ER, 1.0; HR, 1.09; 95% CI, 0.60-1.98) and those 90 years or older (ER, 1.1; HR, 1.20; 95% CI, 0.65-2.22) compared with those aged 70 to 79 years (ER, 0.9). The increase in bleeding risk was sharper in men than in women. Eighty-five patients (2.6%) developed a thrombotic event. Risk of thrombosis was higher for patients in their 90s (HR, 2.14; 95% CI, 1.22-3.75) and 80s (HR, 1.75; 95% CI, 1.002-3.05) than for patients in their 70s. Vitamin K antagonist control became significantly poorer with rising age, which partly explained the increased bleeding risk in patients 90 years or older, but most of the increased risk of thrombosis was not mediated by VKA control. CONCLUSIONS AND RELEVANCE: These clinical practice data of patients considered eligible for anticoagulation show that the bleeding risk with a VKA only mildly increases after the age of 80 years, while there is a sharp increase in the risk of thrombosis in the same age group.
Kooistra et al. (Tue,) conducted a cohort in Patients treated with a vitamin K antagonist (n=3,313). Vitamin K antagonist (VKA) in patients ≥90 years vs. Patients aged 70-79 years was evaluated on Composite of clinically relevant nonmajor and major bleeding (HR 1.26, 95% CI 1.05-1.50). Vitamin K antagonist use in patients ≥90 years was associated with a mildly increased risk of bleeding (HR 1.26; 95% CI 1.05-1.50) and a higher risk of thrombosis compared to patients in their 70s.